LaFleur & Godfrey LLC Acquires 1,419 Shares of Stryker Co. (NYSE:SYK)

LaFleur & Godfrey LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 88,310 shares of the medical technology company’s stock after acquiring an additional 1,419 shares during the quarter. Stryker accounts for approximately 3.9% of LaFleur & Godfrey LLC’s portfolio, making the stock its 4th largest position. LaFleur & Godfrey LLC’s holdings in Stryker were worth $26,445,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Fairfield Bush & CO. acquired a new position in shares of Stryker in the first quarter valued at approximately $131,000. Dimensional Fund Advisors LP grew its position in shares of Stryker by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock valued at $180,182,000 after purchasing an additional 9,026 shares during the last quarter. Prudential PLC bought a new stake in shares of Stryker in the first quarter valued at approximately $1,444,000. Sequoia Financial Advisors LLC boosted its stake in shares of Stryker by 21.6% in the first quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock valued at $817,000 after buying an additional 543 shares during the period. Finally, Zions Bancorporation N.A. boosted its stake in shares of Stryker by 9.2% in the first quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock valued at $839,000 after buying an additional 265 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK traded down $0.14 during mid-day trading on Thursday, hitting $358.57. The company had a trading volume of 381,472 shares, compared to its average volume of 1,312,687. The company has a market capitalization of $136.24 billion, a price-to-earnings ratio of 43.15, a P/E/G ratio of 2.86 and a beta of 0.89. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The stock’s 50-day moving average price is $342.51 and its 200-day moving average price is $305.23.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The firm’s revenue was up 11.8% on a year-over-year basis. On average, sell-side analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is 38.79%.

Analyst Ratings Changes

Several research firms have weighed in on SYK. Royal Bank of Canada restated an “outperform” rating and set a $360.00 target price on shares of Stryker in a research note on Thursday, February 15th. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and increased their price target for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Finally, Truist Financial raised their target price on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research note on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $331.52.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock valued at $72,845,768 in the last 90 days. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.